News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

26 May 2016 U.S. FDA Approves CSL Behring’s AFSTYLA®-- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

> Read More
16 May 2016 CSL Behring Commemorates 2016 hae day :-) with Partnerships, Sponsorships and Hereditary Angioedema Awareness Events

CSL Behring supports HAE Day thru our continued partnership with HAEi & global awareness event sponsorships.

> Read More
13 May 2016 CSL’s Paul Perreault Receives Healthcare CEO Enterprise Award from Philadelphia Alliance for Capital and Technologies

Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault with its 2016 Healthcare CEO Award.

> Read More
11 May 2016 IDELVION® – CSL Behring’s Innovative Therapy for Hemophilia B Patients – Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration

CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein].

> Read More
11 May 2016 European Commission Approves IDELVION® -- CSL Behring’s Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).

> Read More
Page 1 of 52 Next | Last

LinkedIn Twitter Facebook Google+